Reviva Pharmaceuticals Q3 net loss narrows

Reviva Pharmaceuticals Holdings

13/11/2025 21:21

Overview

Reviva reports Q3 net loss of $4 mln, improved from $8.4 mln loss last year

Company plans pre-NDA meeting with FDA for brilaroxazine in Q4 2025

European patent granted for brilaroxazine in pulmonary fibrosis

Outlook

Company plans pre-NDA meeting with FDA for brilaroxazine in Q4 2025

Result Drivers

EQUITY OFFERING - Raised $9 mln through public equity offering to support ongoing research and development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.06
Q3 Net Income
-$4 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $3.00, about 80.7% above its November 12 closing price of $0.58

Press Release: ID:nGNX118MbP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)